Literature DB >> 3928814

Studies on the oxidation of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase B.

R E Heikkila, L Manzino, F S Cabbat, R C Duvoisin.   

Abstract

1-Methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) is a chemical that, after injection into experimental animals, including mice and monkeys, causes a degeneration of the nigrostriatal pathway. We carried out experiments designed to study the in vitro oxidation of MPTP by mouse brain mitochondrial preparations. MPTP was actively oxidized by the mitochondrial preparations, with Km and Vmax values very similar to those of benzylamine, a typical substrate for MAO-B. MPTP was oxidized considerably better than many of its analogs, even those with relatively minor structural changes. Several monoamine oxidase inhibitors (MAOI) were potent inhibitors of MPTP oxidation, and there was a highly significant correlation between the capacity of the MAOI tested to inhibit MPTP oxidation and benzylamine oxidation. There was no correlation between the capacity of the MAOI to inhibit MPTP oxidation and their capacity to inhibit the oxidation of tryptamine, a substrate for MAO-A. In other experiments, MPTP was an excellent substrate for pure MAO-B, prepared from bovine liver. All of these data, combined with the fact that MAO-B inhibitors can protect against MPTP-induced dopaminergic neurotoxicity in vivo, point to an important role for MAO-B in MPTP metabolism in vivo.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3928814     DOI: 10.1111/j.1471-4159.1985.tb05522.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  6 in total

1.  Oxidative polymorphism of debrisoquine in Parkinson's disease.

Authors:  J Benitez; J M Ladero; F J Jimenez-Jimenez; C Martinez; A M Puerto; M J Valdivielso; A Llerena; J Cobaleda; J J Muñoz
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-04       Impact factor: 10.154

2.  Molecular determinants in the bioactivation of the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Authors:  S M Efange; R J Boudreau
Journal:  J Comput Aided Mol Des       Date:  1991-10       Impact factor: 3.686

Review 3.  Clues to the mechanism underlying dopamine cell death in Parkinson's disease.

Authors:  P Jenner
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

4.  Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.

Authors:  Keiko Inaba-Hasegawa; Yukihiro Akao; Wakako Maruyama; Makoto Naoi
Journal:  J Neural Transm (Vienna)       Date:  2012-09-12       Impact factor: 3.575

5.  Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity.

Authors:  R N Kalaria; M J Mitchell; S I Harik
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

6.  The promise of neuroprotective agents in Parkinson's disease.

Authors:  Stacey E Seidl; Judith A Potashkin
Journal:  Front Neurol       Date:  2011-11-21       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.